Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Synthetic Biologics stock | $0.4195

Learn how to easily invest in Synthetic Biologics stock.

Synthetic Biologics Inc is a biotechnology business based in the US. Synthetic Biologics shares (SYN) are listed on the NYSE MKT and all prices are listed in US Dollars. Synthetic Biologics employs 10 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Synthetic Biologics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SYN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Synthetic Biologics stock price (NYSE MKT: SYN)

Use our graph to track the performance of SYN stocks over time.

Synthetic Biologics shares at a glance

Information last updated 2021-10-23.
Latest market close$0.42
52-week range$0.28 - $1.22
50-day moving average $0.46
200-day moving average $0.52
Wall St. target price$1.88
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.31

Buy Synthetic Biologics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Synthetic Biologics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Synthetic Biologics price performance over time

Historical closes compared with the close of $0.4195 from 2021-10-26

1 week (2021-10-20) -4.22%
1 month (2021-09-27) -14.42%
3 months (2021-07-27) -17.75%
6 months (2021-04-27) -29.47%
1 year (2020-10-27) 30.24%
2 years (2019-10-25) 0.87%
3 years (2018-10-26) 0.84
5 years (2016-10-27) 1.39

Synthetic Biologics financials

Gross profit TTM $0
Return on assets TTM -14.36%
Return on equity TTM -25.08%
Profit margin 0%
Book value $0.58
Market capitalisation $53.6 million

TTM: trailing 12 months

Shorting Synthetic Biologics shares

There are currently 12,168 Synthetic Biologics shares held short by investors – that's known as Synthetic Biologics's "short interest". This figure is 48.9% down from 23,802 last month.

There are a few different ways that this level of interest in shorting Synthetic Biologics shares can be evaluated.

Synthetic Biologics's "short interest ratio" (SIR)

Synthetic Biologics's "short interest ratio" (SIR) is the quantity of Synthetic Biologics shares currently shorted divided by the average quantity of Synthetic Biologics shares traded daily (recently around 1.2 million). Synthetic Biologics's SIR currently stands at 0.01. In other words for every 100,000 Synthetic Biologics shares traded daily on the market, roughly 10 shares are currently held short.

However Synthetic Biologics's short interest can also be evaluated against the total number of Synthetic Biologics shares, or, against the total number of tradable Synthetic Biologics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Synthetic Biologics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Synthetic Biologics shares in existence, roughly 0 shares are currently held short) or 0.0001% of the tradable shares (for every 100,000 tradable Synthetic Biologics shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Synthetic Biologics.

Find out more about how you can short Synthetic Biologics stock.

Synthetic Biologics share dividends

We're not expecting Synthetic Biologics to pay a dividend over the next 12 months.

Have Synthetic Biologics's shares ever split?

Synthetic Biologics's shares were split on a 1:35 basis on 12 August 2018. So if you had owned 35 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Synthetic Biologics shares – just the quantity. However, indirectly, the new 3400% higher share price could have impacted the market appetite for Synthetic Biologics shares which in turn could have impacted Synthetic Biologics's share price.

Synthetic Biologics share price volatility

Over the last 12 months, Synthetic Biologics's shares have ranged in value from as little as $0.2833 up to $1.22. A popular way to gauge a stock's volatility is its "beta".

SYN.US volatility(beta: 1.81)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Synthetic Biologics's is 1.8085. This would suggest that Synthetic Biologics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Synthetic Biologics overview

Synthetic Biologics, Inc. , a clinical-stage company, develops therapeutics to treat gastrointestinal (GI) diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in GI tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. The company also develops clinical stage products, such as SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004.

Frequently asked questions

What percentage of Synthetic Biologics is owned by insiders or institutions?
Currently 1.765% of Synthetic Biologics shares are held by insiders and 4.962% by institutions.
How many people work for Synthetic Biologics?
Latest data suggests 10 work at Synthetic Biologics.
When does the fiscal year end for Synthetic Biologics?
Synthetic Biologics's fiscal year ends in December.
Where is Synthetic Biologics based?
Synthetic Biologics's address is: 9605 Medical Center Drive, Rockville, MD, United States, 20850
What is Synthetic Biologics's ISIN number?
Synthetic Biologics's international securities identification number is: US87164U2015
What is Synthetic Biologics's CUSIP number?
Synthetic Biologics's Committee on Uniform Securities Identification Procedures number is: 724153101

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site